Preferential loss of mismatch repair function in refractory and relapsed acute myeloid leukemia: Potential contribution to AML progression

Cell Research

Volumn 18, Issue 2, 2008, Pages 281-289

  Mao, Guogen ^a   Yuan, Fenghua ^a   Absher, Kimberly ^a   Jennings, C Darrell ^a   Howard, Dianna S ^a   Jordan, Craig T ^b   Gu, Liya ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Hypermethylation; Leukemia relapse; MLH1; MSH2

Indexed keywords

MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BIOSYNTHESIS; CHILD; DNA METHYLATION; FEMALE; GENETICS; HUMAN; INFANT; MALE; METABOLISM; MIDDLE AGED; MISMATCH REPAIR; MUTATION; PATHOLOGY; PRESCHOOL CHILD; PROMOTER REGION; RECURRENT DISEASE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; DNA MISMATCH REPAIR; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); RECURRENCE;

EID: 38849153665     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2008.14     Document Type: Article

References (38)

1. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106:1154-1163.
2. Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005; 23:6285-6295.
3. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007; 109:431-448.
4. Kolodner RD, Marsischky GT. Eukaryotic DNAmismatch repair. Curr Opin Genet Dev 1999; 9:89-96.
5. Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem 2005;74:681-710.
6. Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem 1996;65:101- 133.
7. Li GM. The role of mismatch repair in DNA damage-induced apoptosis. Oncol Res 1999; 11:393-400.
8. Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res 2008; 18:85-98.
9. Tasaka T, Lee S, Spira S, et al. Microsatellite instability during the progression of acute myelocytic leukaemia. Br J Haematol 1997;98:219-221.
10. Das-Gupta EP, Seedhouse CH, Russell NH. Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol 2001; 114:307-312.
11. Krskova-Honzatkova L, Cermak J, Sajdova J, Stary J, Sedlacek P, Sieglova Z. Microsatellite instability in hematological malignancies. LeukLymphoma 2002; 43:1979-1986.
12. Sheikhha MH, Tobal K, Liu Yin JA. High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 2002; 117:359-365.
13. Zhu YM, Das-Gupta EP, Russell NH. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood 1999; 94:733-740.
14. Rimsza LM, Kopecký KJ, Ruschulte J, et al. Microsatellite instability is not a defining genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature. Leukemia 2000; 14:1044-1051.
15. Gu L, Cline-Brown B, Zhang F, Qiu L, Li GM. Mismatch repair deficiency in hematological malignancies with microsatellite instability. Oncogene 2002; 21:5758-5764.
16. Casorelli I, Offman J, Mele L, et al. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair (Amst) 2003; 2:547-559.
17. Friedman HS, Johnson SP, Dong Q, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997; 57:2933-2936.
18. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 1993; 90:6424-6428.
19. Mao G, Pan X, Gu L. Evidence that a mutation in the MLHl 3′ untranslated region confers a mutator phenotype and mismatch repair deficiency in patients with relapsed leukemia. J Biol Chem 2007 Dec 4; doi: 10.1074/jbc.M709276200.
20. BaylinSB,HermanJG.DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16:168-174.
21. Herman JG, Baylin SB. Promoter-region hypermethylation and gene silencing in human cancer. Curr Top Microbiol Immunol 2000; 249:35-54.
22. Cejka P, Stojic L, Mojas N, et al. Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO /2003; 22:2245-2254.
23. Zhang Y, Yuan F, Presnell SR, et al. Reconstitution of 5′-directed human mismatch repair in a purified system. Cell 2005; 122:693-705.
24. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36:801-818.
25. Kolodner RD, Alani E. Mismatch repair and cancer susceptibility. Curr Opin Biotechnol 1994; 5:585-594.
26. Kouri M, Laasonen A, Mecklin JP, Jarvinen H, Franssila K, Pyrhonen S. Diploid predominance in hereditary nonpolyposis colorectal carcinoma evaluated by flow cytometry. Cancer 1990; 65:1825-1829.
27. Buermeyer AB, Deschenes SM, Baker SM, Liskay RM. Mammalian DNA mismatch repair. Annu Rev Genet 1999; 33:533-564.
28. Raanani P, Ben-Bassat I. Detection of minimal residual disease in acute myelogenous leukemia. Acta Haematol 2004; 112:40-54.
29. Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96:3948-3952.
30. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood2004; 104:3078-3085.
31. Kern W, Schoch C, Haferlach T, Schnittger S. Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol 2005; 56:283-309.
32. Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 2001; 22:1931-1937.
33. Wu J, Gu L, Wang H, Geacintov NE, Li GM. Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis. Mol Cell Biol 1999; 19:8292-8301.
34. Wu J, Zhu BB, Yu J, et al. In vitro and in vivo modulations of benzo[c]phenanthrene-DNA adducts by DNA mismatch repair system. Nucl Acids Res 2003; 31:6428-6434.
35. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21:4642-4649.
36. Murata H, Khattar NH, Kang Y, Gu L, Li GM. Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLHl in sporadic breast cancer with microsatellite instability. Oncogene 2002; 21:5696-5703.
37. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95:6870-6875.
38. Holmes J Jr, Clark S, Modrich P. Strand-specific mismatch correction in nuclear extracts of human and Drosophila melanogaster cell lines. Proc Natl Acad Sci USA 1990; 87:5837-5841.